KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.

David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T Hooper, Jennifer D Hamilton, Bret J Musser, Diana Rofail, Mohamed Hussein, Joseph Im, Dominique Y Atmodjo, Christina Perry, Cynthia Pan, Adnan Mahmood, Romana Hosain, John D Davis, Kenneth C Turner, Alina Baum, Christos A Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Lilia Roque-Guerrero, Gerard Acloque, Hessam Aazami, Kevin Cannon, J Abraham Simón-Campos, Joseph A Bocchini, Bari Kowal, A Thomas DiCioccio, Yuhwen Soo, Gregory P Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D Yancopoulos, Trial Investigators

N Engl J Med 385(23) e81

PMID34587383
PMCIDPMC8522800
DOI10.1056/NEJMoa2108163
发表日期2021-09-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. METHODS: In the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19 and risk factors for severe disease to receive various doses of intravenous REGEN-COV or placebo. Patients were followed through day 29. A prespecified hierarchical analysis was used to assess the end points of hospitalization or death and the time to resolution of symptoms. Safety was also evaluated. RESULTS: Covid-19-related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P = 0.002). The median time to resolution of symptoms was 4 days shorter with each REGEN-COV dose than with placebo (10 days vs. 14 days; P<0.001 for both comparisons). REGEN-COV was efficacious across various subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. Both REGEN-COV doses reduced viral load faster than placebo; the least-squares mean difference in viral load from baseline through day 7 was -0.71 log10 copies per milliliter (95% confidence interval [CI], -0.90 to -0.53) in the 1200-mg group and -0.86 log10 copies per milliliter (95% CI, -1.00 to -0.72) in the 2400-mg group. Serious adverse events occurred more frequently in the placebo group (4.0%) than in the 1200-mg group (1.1%) and the 2400-mg group (1.3%); infusion-related reactions of grade 2 or higher occurred in less than 0.3% of the patients in all groups. CONCLUSIONS: REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04425629.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。